ProQR Therapeutics (NASDAQ:PRQR) Receives $8.00 Consensus Target Price from Analysts

ProQR Therapeutics (NASDAQ:PRQR) has received a consensus rating of “Buy” from the eight research firms that are presently covering the stock, MarketBeat.com reports. Seven analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $8.00.

A number of equities analysts have recently weighed in on PRQR shares. Evercore ISI initiated coverage on ProQR Therapeutics in a report on Tuesday, April 29th. They issued an “outperform” rating and a $5.00 target price on the stock. Citigroup raised ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 target price for the company in a research report on Monday, March 10th. Cantor Fitzgerald assumed coverage on ProQR Therapeutics in a research report on Tuesday, April 29th. They issued an “overweight” rating and a $8.00 price objective for the company. Oppenheimer reduced their target price on ProQR Therapeutics from $15.00 to $9.00 and set an “outperform” rating for the company in a research report on Tuesday, May 13th. Finally, HC Wainwright raised their target price on ProQR Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, March 14th.

Hedge Funds Weigh In On ProQR Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Jane Street Group LLC bought a new stake in ProQR Therapeutics in the 4th quarter valued at about $30,000. Invesco Ltd. bought a new stake in ProQR Therapeutics in the fourth quarter valued at approximately $32,000. Alpine Global Management LLC bought a new position in shares of ProQR Therapeutics during the fourth quarter valued at approximately $39,000. Two Sigma Securities LLC bought a new position in ProQR Therapeutics in the fourth quarter worth $40,000. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of ProQR Therapeutics in the fourth quarter worth $54,000. 32.65% of the stock is owned by hedge funds and other institutional investors.

ProQR Therapeutics Stock Down 4.2%

PRQR stock opened at $1.83 on Thursday. ProQR Therapeutics has a fifty-two week low of $1.07 and a fifty-two week high of $4.62. The company has a market capitalization of $192.54 million, a P/E ratio of -5.72 and a beta of 0.31. The company has a 50-day simple moving average of $1.51 and a 200 day simple moving average of $2.12.

ProQR Therapeutics (NASDAQ:PRQR) last posted its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.02). The company had revenue of $4.89 million for the quarter, compared to analyst estimates of $4.90 million. ProQR Therapeutics had a negative return on equity of 71.58% and a negative net margin of 134.31%. Equities analysts anticipate that ProQR Therapeutics will post -0.31 EPS for the current year.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).